Drugs in MeSH Category Adjuvants, Anesthesia

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Sub Teva Pharms	DIAZEPAM	diazepam	TABLET;ORAL	071307-001	Dec 10, 1986	AB	RX	No	No
Solopak	DROPERIDOL	droperidol	INJECTABLE;INJECTION	071755-001	Sep 6, 1988		DISCN	No	No
Ph Health	GLYCOPYRROLATE	glycopyrrolate	SOLUTION;ORAL	204438-001	Aug 9, 2021	AA	RX	No	No
Regcon Holdings	DIAZEPAM	diazepam	INJECTABLE;INJECTION	211998-001	Dec 26, 2019	AP	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Adjuvants, Anesthesia

Last updated: April 24, 2026

What is the MeSH scope for “Adjuvants, Anesthesia,” and how does it map to investable drug categories?

The NLM MeSH category “Adjuvants, Anesthesia” captures pharmacologic agents used to enhance anesthesia, manage perioperative pain, modulate perioperative physiology, or reduce adverse events in conjunction with anesthetics. In practice, the category spans four investable drug lines that drive both demand and patent activity:

1. Adjunct analgesics for perioperative use
   • α2-agonists (sedation/analgesia), NMDA antagonists in some indications, systemic adjuncts used with surgical anesthesia
2. Antiemetics used perioperatively
   • 5-HT3 antagonists, NK1 pathway agents, D2 antagonists, corticosteroids used for PONV prophylaxis
3. Local anesthetic adjuvants and regional anesthesia adjuncts
   • adjuvant components used in neuraxial or peripheral nerve blocks (opioid combinations, adjunct strategies, catheter-based formulations)
4. Reverse agents and perioperative supportive drugs
   • reversal of anesthetic-associated effects (where claimed), perioperative rescue agents, supportive infusions that are used under anesthesia protocols

From a market-operations standpoint, these products share three economics: they sell into anesthesia workflows (hospital formularies), they are judged by perioperative outcomes (PONV, recovery profile, opioid-sparing), and they face recurring competition from generics and label carve-outs.

What are the market dynamics shaping demand in perioperative anesthesia adjuvants?

Perioperative “adjunct” demand is driven less by chronic patient volume and more by procedure mix, guideline adherence, and hospital contracting. Key dynamics:

1) Formulary leverage and bundled anesthesia contracting

Hospitals purchase anesthesia-related drugs through group purchasing organizations (GPOs), wholesaler agreements, and formulary committees. This pushes differentiation toward:

• dosing convenience (single-dose, ready-to-use, smaller infusion footprint)
• reduced nursing time (less monitoring, less rescue)
• fewer post-discharge complications that cause downstream utilization

2) Outcomes-based pressure: PONV, recovery time, and opioid-sparing

Anesthesia-adjunct uptake correlates with measured outcomes:

• lower incidence and severity of postoperative nausea and vomiting (PONV)
• improved recovery endpoints (time to discharge readiness, respiratory stability)
• pain control that reduces perioperative opioid exposure

3) Safety and controlled-substance constraints

Adjuncts that reduce opioids or stabilize respiration gain traction because hospitals face:

• tighter opioid stewardship policies
• respiratory-risk scrutiny post anesthesia
• payer and regulator attention on adverse events

4) Generic substitution waves

Many anesthesia-adjunct molecules have long patent histories, and many perioperative drug classes carry:

• early generic penetration once primary composition patents expire
• value shifts toward formulation IP, delivery systems, and label expansion
• competitive intensity around the same MeSH-adjacent workflows (e.g., PONV prophylaxis protocols)

5) Regulatory and evidence requirements

Label expansions and line extensions require robust clinical packages, usually:

• randomized perioperative trials
• subgroup claims (outpatient vs inpatient, adult vs pediatric, surgeries with higher PONV rates)
• endpoints tied to anesthetic workflow decisions

What does the patent landscape look like for anesthesia adjuvants?

The patent landscape for this MeSH scope is structurally dominated by five IP categories. Each drives a different “time-to-expiration” shape for competitive risk:

A) Composition-of-matter (CoM) patents on active ingredients

• Build the first wave of exclusivity for new molecular entities.
• Risk: CoM expiry triggers generic entry unless protected by formulation or new method claims.

B) Formulation and delivery patents

• Examples of claim strategies in this space include:
  • ready-to-use, stabilized compositions
  • multi-drug fixed-dose combinations (when permitted)
  • sustained-release or targeted delivery concepts
• Risk: formulation patents can be strong, but they can also be designed around.

C) Method-of-use patents tied to perioperative protocols

• Common claim themes:
  • prophylaxis regimens for PONV (timing and dose schedules)
  • perioperative analgesic regimens with specified endpoints
  • regional anesthesia adjuvant regimens
• Risk: “practice” depends on physician behavior, but payers and hospital protocols can stabilize uptake.

D) Device-adjacent patents (where drug + delivery is integral)

• Catheter-based delivery, infusion systems, and mixing systems
• Risk: device IP can extend practical exclusivity even after drug CoM expires.

E) Polymorph/particle/solid-state control (where relevant)

• Some perioperative drugs have opportunities for solid-state exclusivity.
• Risk: often narrower than CoM and susceptible to design-around.

Which MeSH-adjacent drug classes have the most recurring patent activity?

Patent activity clusters around drug lines that face repeated clinical protocol opportunities:

1. PONV prophylaxis and rescue
   • Claims typically focus on timing, combinations, and patient risk stratification
2. Sedation and opioid-sparing perioperative analgesia
   • Claims target adjunct role, dosing ranges, and perioperative settings (PACU, outpatient)
3. Regional anesthesia adjuvants
   • Claims focus on compatibility with local anesthetics, dosing, and outcome endpoints
4. Anesthetic reversal and perioperative rescue
   • Claims may focus on use with specific anesthetic agents or perioperative scenarios

How does exclusivity usually decay in this therapeutic area?

A typical exclusivity decay pattern for anesthesia adjuvants:

• Near term (0-5 years): strong differentiation in clinical protocols plus formulation convenience
• Mid term (5-10 years): competitors target label-adjacent expansions, dosing simplification, and combination strategies
• Late term (10+ years): generic pressure dominates; remaining defensibility shifts to:
  • narrow method-of-use claims that remain relevant
  • delivery system IP
  • brand-specific hospital contracting

This creates an investment pattern: the most actionable patent shelf life is often in formulation and method-of-use claims that survive CoM expiry waves.

What are the most important “market risk” mechanisms for patent holders?

Patent holders face four recurring threats:

1. Generic entry with label carve-outs
   • Competitors launch under narrower indications or different patient selection.
2. Design-around of formulation IP
   • Equivalent active ingredients with different stabilizers, presentation, or dosing schedule.
3. Protocol shift
   • If clinical practice moves toward different perioperative pathways, method-of-use patents lose practical value.
4. Payer pressure
   • Utilization management tools reduce uptake even when the clinical value remains.

What is the patent landscape search logic for this MeSH class (actionable framework)?

For rigorous mapping of patent risk and opportunity, the operational search strategy for “Adjuvants, Anesthesia” should align the MeSH scope with patent families that claim one of the following:

• Perioperative method-of-use claims
  • endpoints like PONV prevention, analgesia in PACU, sedation endpoints
  • timing claims relative to induction, surgery start, incision, or PACU admission
• Formulation claims
  • stability, dosing presentation, infusion parameters
• Regional anesthesia claims
  • adjuvant combinations with local anesthetics and delivery modality
• Combination regimens
  • fixed combinations or sequential protocols

MeSH itself is an indexing standard for biomedical literature. For patent landscape work, you map MeSH concepts to:

• drug ingredient terms
• formulation and dosing terms
• surgery and perioperative protocol terms
• adverse event endpoints (PONV, pain scores, rescue drug criteria)

What are the competitive dynamics for hospital adoption?

Hospital adoption is highly sensitive to workflow fit:

• Administration burden: fewer steps, shorter preparation time, less infusion complexity
• Rescue requirements: lower rescue rates in PONV or inadequate analgesia
• Recovery metrics: faster readiness for discharge
• Staff training burden: limited need for specialized nursing protocols
• Contracting: price-volume agreements and preferred-drug tiers

Brand differentiation survives when it reduces operational friction and rescue utilization, not only when it improves average clinical outcomes.

Key implications for R&D planning and portfolio defense

1) Defensibility depends on claim type, not just drug class

When CoM is weak or aging, successful defense commonly comes from:

• method-of-use claims aligned with entrenched hospital protocols
• formulation IP that reduces administration friction
• delivery concepts that are harder to substitute

2) Evidence strategy must match hospital endpoints

Perioperative decision-makers prioritize measured endpoints:

• PONV incidence and severity
• pain control with fewer opioid rescue doses
• discharge readiness and respiratory safety

3) Timing matters: pipeline and filing windows should target “protocol adoption”

Late-stage claims that mirror real hospital regimens often retain value longer than claims that require niche practice.

Key Takeaways

• “Adjuvants, Anesthesia” maps to multiple high-throughput perioperative drug workflows, especially PONV management, opioid-sparing analgesic adjuncts, and regional anesthesia adjuvant strategies.
• Demand is driven by procedure mix, hospital formularies, and perioperative outcomes (PONV, recovery endpoints, rescue reduction).
• The patent landscape is dominated by method-of-use, formulation/delivery, and protocol-aligned combination IP rather than CoM alone.
• Patent value decays fastest when clinical protocols shift or when generic substitution competes on administration convenience and label breadth.
• For R&D and portfolio defense, the most actionable claims are those that remain consistent with real perioperative practice and minimize substitution friction.

FAQs

What patient populations matter most in this MeSH scope?

Perioperative adult and pediatric surgical populations, with emphasis on PONV-risk strata and settings that include PACU and outpatient discharge pathways.

Which endpoints typically support method-of-use claims for anesthesia adjuvants?

PONV incidence/severity, analgesia adequacy and rescue rates, time-to-recovery or discharge readiness, and safety endpoints tied to perioperative respiratory stability.

Do formulation patents usually add meaningful exclusivity after CoM expiry?

They can, especially when the formulation reduces administration steps, improves stability, or enables a practical dosing workflow that supports label claims.

How do hospitals decide between brand and generic in this area?

They weigh contract pricing and availability against workflow fit, rescue utilization, recovery impact, and training burden.

What is the strongest patent claim posture for long-term defensibility?

Claims that align with standardized perioperative protocols, including timing and patient-risk criteria, and that pair drug with delivery or presentation constraints that are hard to replicate.

---

References

[1] National Library of Medicine. MeSH (Medical Subject Headings): Adjuvants, Anesthesia. https://meshb.nlm.nih.gov/
[2] U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] World Health Organization. WHO Classification of Anatomical Therapeutic Chemical (ATC) and related guidance (for mapping perioperative drug classes). https://www.who.int/teams/health-product-policy-standards/standardization-other-tools/atc-ddd-toolkit